Contact UsCareers
Top bar

Ayala Pharmaceuticals

News & Events

Ayala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update

- Presented N ew P ositive I nterim D ata from 4mg C ohort of Phase 2 ACCURACY S tudy of AL101 for the T reatment of R/M ACC at European Society for Medical Oncology 2020 - - Trial In Progress Poster of Phase 2 TENACITY Study of AL101 Monotherapy in Patients w ith Notch-activated Triple-Negative

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102). Ayala’s lead product candidate, AL101, is currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations (ACCURACY)

Contacts

Investors

Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
Julie.seidel@sternir.com

 

Ayala Pharmaceuticals
+1-857-444-0553
info@ayalapharma.com

 

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102). Ayala’s lead product candidate, AL101, is currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations (ACCURACY)

Contacts

Investors

Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
Julie.seidel@sternir.com

 

Ayala Pharmaceuticals
+1-857-444-0553
info@ayalapharma.com